Shots:

• The P-I study assesses the PK- safety- tolerability and immunogenicity of SB17 vs Stelara (US & EU sourced) in 201 healthy males in a ratio (1:1:1) aged 18-55yrs. All IPs will be administered subcutaneously in the abdomen
• Samsung Bioepis has four biosimilar candidates – SB12 (eculizumab)- SB15 (aflibercept)- and SB16 (denosumab) in P-III and SB17 (ustekinumab) in P-I clinical trial
• With the initiation- Samsung Bioepis continues to advance its biosimilar portfolio covering immunology- oncology- ophthalmology- and hematology

 ­ Ref: Samsung Bioepis | Image: Samsung Bioepis